---
title: "What to Look for When Selecting a CRO for IVD Performance Studies"
description: "Not every CRO is equipped for IVD performance studies. Learn the nine capabilities that matter most for compliant, defensible evidence generation."
url: https://qbdgroup.com/en/blog/selecting-cro-ivd-performance-studies
type: "Blog post"
language: en
published: 2026-05-20
author: "Annelies Rotthier & Kirsten Van Garsse"
category: "Clinical"
publisher: "QbD Group"
citation: "QbD Group, \"What to Look for When Selecting a CRO for IVD Performance Studies\", https://qbdgroup.com/en/blog/selecting-cro-ivd-performance-studies"
---
# What to Look for When Selecting a CRO for IVD Performance Studies
> Not every CRO is equipped for IVD performance studies. Learn the nine capabilities that matter most for compliant, defensible evidence generation.

Whether you are a diagnostic manufacturer planning a standalone performance study or a pharmaceutical company coordinating a companion diagnostic (CDx) co-development program, there is a high probability that a Contract Research Organization (CRO) will play a role in your IVD performance study.

The question is not *whether* you will engage an external partner. The question is: *which one*, and whether they have the **right capabilities for the job**.

This matters more than it might initially seem.

IVD performance studies are fundamentally different from pharmaceutical clinical trials, and selecting a CRO without IVD-specific expertise can introduce:

- compliance risks,
- study delays,
- and evidence that may not adequately support regulatory submissions.

Here are the key areas we recommend evaluating.

## IVD-Specific Scientific and Operational Expertise

This is the **first and most important filter**.

A CRO with a strong background in pharmaceutical clinical trials does not automatically have the expertise required for IVD performance studies.

IVDs differ from pharmaceuticals and other medical devices in:

- design,
- validation,
- clinical evaluation,
- and specimen strategy.

These differences directly influence:

- study design,
- biomarker strategy,
- and performance evaluation requirements.

Look for a partner with:

- direct experience managing IVD performance studies,
- knowledge of specimen-based study designs,
- and familiarity with biomarker-driven development strategies.

Ask for **concrete examples** of previous IVD studies they have supported.

## Performance Study Strategy

A strong IVD CRO does not simply execute a protocol. **It helps shape one.**

The CRO should be able to:

- translate the device's intended purpose into an appropriate study design,
- advise on specimen procurement and inclusion criteria,
- support cut-off definition and matrix effect considerations,
- and ensure real-world representativeness of the study population.

Most importantly, the study must generate evidence aligned with the intended regulatory pathway, whether for:

- IVDR conformity assessment,
- United States Food and Drug Administration (FDA) Investigational Device Exemption (IDE) requirements,
- or both.

## Regulatory Knowledge Across Frameworks

Your CRO should have practical experience with:

- IVDR performance study requirements under Articles 57–77,
- Annex XIII and Annex XIV documentation expectations,
- and European Union (EU) Member State submission processes.

This includes understanding:

- authorization versus notification pathways,
- country-specific submission differences,
- and risk classification implications.

If your program includes a US component, experience supporting **FDA IDE requirements** for IVD and CDx studies is equally important.

## Quality Management System (QMS) and Compliance Infrastructure

A CRO active in the IVD performance study space should operate under a quality framework aligned with:

- ISO 13485,
- and processes consistent with ISO 20916 Good Study Practice.

This includes structured approaches to:

- monitoring,
- specimen accountability,
- study governance,
- and documentation control.

These are not optional extras. They form the **operational foundation for generating defensible evidence**.

## Risk-Based Monitoring Capability

Risk-based oversight approaches are increasingly expected under:

- ISO 20916,
- and broader IVDR expectations.

Your CRO should be capable of designing and implementing a risk-based monitoring strategy tailored to:

- study complexity,
- device risk,
- and site performance.

This includes both:

- on-site monitoring,
- and remote oversight approaches.

## Data Management Excellence

IVD performance studies often involve:

- specimen-linked datasets,
- traceability requirements,
- and complex data reconciliation activities.

The CRO should therefore have strong capabilities in:

- electronic data capture,
- data validation,
- query management,
- audit readiness,
- and data integrity controls.

Experience handling the **unique traceability challenges** of IVD studies is critical.

## Medical Writing and Regulatory Documentation

High-quality documentation is not optional. **It is a regulatory deliverable.**

Ensure your CRO has proven experience preparing:

- Performance Study Plans (PSPs),
- informed consent forms,
- investigator brochures,
- study reports,
- and broader regulatory documentation specifically within the IVD clinical performance domain.

## Safety Reporting and Adverse Event Management

Even within IVD performance studies, safety reporting obligations remain essential.

Your CRO should be able to:

- implement Sponsor-aligned safety reporting processes,
- manage adverse event (AE) and serious adverse event (SAE) reconciliation,
- prepare draft regulatory notifications,
- and support follow-up and corrective actions when needed.

## Project Management Discipline

This is one area we frequently see **underestimated**.

Strong project management infrastructure often determines whether a study:

- remains aligned and on schedule,
- or slowly drifts into delays and operational confusion.

Evaluate whether the CRO has mature systems for:

- timeline management,
- budget oversight,
- risk tracking,
- change control,
- and multisite coordination.

This becomes especially important in combined studies involving multiple Sponsors, stakeholders, and regulatory workstreams.

![CRO Selection Checklist for IVD Clinical Performance Studies — nine essential capabilities](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/blog-images/selecting-cro-ivd-performance-studies-visual.jpg)

## A Partner, Not Just a Vendor

The right CRO for an IVD performance study is not simply operationally capable. It understands:

- the regulatory context,
- the strategic importance of the generated evidence,
- and the specific challenges associated with IVD performance studies.

Selecting a CRO with this depth of expertise supports:

- regulatory compliance,
- stronger clinical evidence quality,
- and ultimately **faster and more predictable pathways to market**.

## Want the Full Strategic Framework?

For a broader overview of Sponsor responsibilities, delegation frameworks, sponsorship models, and governance structures for IVD performance studies, download our white paper *Sponsor Responsibilities in IVD Clinical Performance Studies*.

**[Sponsor Responsibilities in IVD Clinical Performance Studies →](/en/whitepapers/sponsor-responsibilities-ivd-performance-studies)**

## Looking for Support Selecting or Managing an IVD CRO?

At QbD Group, we support pharmaceutical companies, biotech firms, and IVD manufacturers in structuring performance study governance, evaluating CRO capabilities, and building compliant operational frameworks aligned with IVDR and FDA expectations.

Want to discuss how to select the right CRO for your IVD performance study? **[Talk to our experts](/en/contact)** and build the right operational foundation from the start.
---
Source: https://qbdgroup.com/en/blog/selecting-cro-ivd-performance-studies — © QbD Group. Quote freely with attribution and a link back.